In a surprising move, President Trump has signed an order to accelerate access to psychedelic drug treatments, including ibogaine, LSD, and psilocybin. This decision comes amidst growing interest in the therapeutic potential of these substances, particularly in mental health care.
Notably, Joe Rogan played a key role in persuading Trump to fast-track the review process for these psychedelics. The implications of this order could reshape the landscape of addiction treatment and mental health therapies in the U.S., as more patients may gain access to these controversial yet promising substances.